In a major relief for millions of patients across India, the Central Government has reduced the retail prices of 39 essential medicines used to treat chronic diseases such as diabetes, hypertension (high blood pressure), and cardiovascular disorders. The decision has been made by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs (Prices Control) Order, 2013 (DPCO 2013).
And if it’s a permanent and long-term solution that doesn’t work, money will be saved, at least for people with life-saving medicines such as cancer patients and those with chronic illnesses. With expensive medical care mounting, the decision will help to ease the burden on millions of low- and middle-income families.
Relief for Patients with Chronic Diseases
Diabetes, hypertension, and heart-related diseases are among the most common chronic health conditions in India. These diseases can be so severe that patients will have to take medication for many years and, at times, even the rest of their lives.
Hence, monthly medicine expenses make up the bulk of household budgets. So the government is trying to keep these essential drugs affordable for all communities and make sure that quality medicines are affordable to everybody.
Even though the price reduction of individual medicines may seem modest, the cumulative savings over months and years can be significant for patients on continuous medication.
NPPA Gives Strict Directions to Pharma Companies
According to the NPPA's latest notification, all pharmaceutical manufacturers have been instructed to immediately revise the Maximum Retail Price (MRP) of the affected medicines in line with the newly approved price ceiling.
Companies will update product packaging, and the new prices will be reflected in the supply chain in no time.
This is done to prevent price escalation and to provide the consumers with needed medicines at fair and regulated prices, the authority said.
Warning Against Overpricing and Artificial Shortages
The NPPA has also issued a stern warning to pharmaceutical companies and medicine distributors against violating the revised pricing norms.
Any company selling medicines above the approved ceiling price or creating artificial shortages to manipulate the market could face strict legal action under the provisions of the Drugs (Prices Control) Order, 2013, and other applicable regulations.
The government has also made clear that it would not allow consumers to face unjustified price hikes, but that essential medicines would be available to consumers.
In the future, affordable healthcare is still a priority
The decision is part of a wider government push to improve affordable healthcare and cut out-of-pocket medical expenses for the people. By controlling the prices of essential medicines, authorities aim to improve treatment adherence among patients who often struggle with the cost of long-term therapy.
Relatively affordable medicines allow patients to continue their prescribed treatments without interruption and thereby reduce the risk of complications associated with chronic diseases, healthcare experts say.
The price caps will help millions of people with diabetes, hypertension, heart ailments, and other chronic medical conditions in the country, and the government’s focus on accessible and affordable healthcare is strong now.
